TransCode Therapeutics, Inc. (NASDAQ: RNAZ), a clinical-stage company focused on RNA-based therapeutics for cancer, has announced the appointment of Anna Moore, PhD, as Chair of its Scientific Advisory Board and the execution of a sponsored research agreement with Michigan State University. These developments aim to bolster the company's pipeline, particularly its lead candidate TTX-MC138, which targets metastatic tumors overexpressing microRNA-10b.
The research agreement with Michigan State University is expected to support the development of TTX-MC138, including evaluation in combination with other therapies. This collaboration leverages academic expertise to potentially enhance the therapeutic efficacy of TransCode's lead candidate. Dr. Moore, a renowned expert in molecular imaging and nanomedicine, will provide strategic guidance on research and development efforts focused on treating advanced cancers. Her appointment underscores TransCode's commitment to advancing its pipeline through expert leadership.
TransCode Therapeutics is pioneering immuno-oncology and RNA-based approaches for high-risk and advanced cancers. Its lead candidate, TTX-MC138, targets microRNA-10b, a biomarker of metastasis, offering a novel therapeutic strategy. The company also has a portfolio of other first-in-class candidates designed to mobilize the immune system to recognize and destroy cancer cells.
These announcements are significant as they strengthen TransCode's scientific foundation and collaborative network. The appointment of Dr. Moore brings decades of experience in cancer research and drug development, while the Michigan State University agreement provides resources for preclinical and clinical development. Together, these moves could accelerate the progress of TTX-MC138 and other pipeline assets, potentially improving outcomes for patients with advanced cancers.
For more details, the full press release is available at https://ibn.fm/NA2NH. Investors can also access the latest news and updates regarding RNAZ at the company's newsroom: https://ibn.fm/RNAZ.
